Chronic limb-threatening ischemia: rest pain, wounds and limb care

Direct answer. Chronic limb-threatening ischemia is advanced arterial disease associated with rest pain or tissue loss such as a nonhealing ulcer or gangrene. It requires prompt vascular assessment and coordinated circulation, wound and infection care. A painless diabetic wound can still be serious. current PAD context.

Table of contents

• Evidence summary: assess circulation, wounds and infection together
• What is chronic limb-threatening ischemia, or CLTI?
• Poor perfusion, nerve injury and infection can reinforce one another
• Revascularisation and local wound care need coordinated planning
• Wound-healing claims require human clinical evidence
• Protect the foot and make the care plan practical
• Know when the limb or an infection needs emergency care
• Clot-prevention and cholesterol medicines need separate safety review
• Testing links the wound to objective arterial perfusion
• Amputation decisions, recovery and goals need explicit discussion
• Cell, gene and vessel-growth findings are not routine treatment proof
• Funding and source roles
• Frequently asked questions
• Sources and funding notes

Evidence summary: assess circulation, wounds and infection together

Confidence is high that persistent foot wounds and severe rest symptoms need prompt medical assessment. NHS education describes this advanced arterial complication, sometimes called critical limb ischaemia or CLI. Sudden deterioration and suspected gangrene require emergency care. current symptom context; gangrene safety.

This guide attributes treatment planning to clinical guidelines and separates it from independent efficacy. It does not rank devices, compare unsupported limb-salvage percentages or treat a nonprofit publisher as proof that all its authors and trials are financially independent.

What is chronic limb-threatening ischemia, or CLTI?

CLTI is an advanced peripheral artery disease syndrome with inadequate arterial supply associated with ischemic rest pain, nonhealing ulceration or gangrene. The original 2019 global guideline prefers CLTI to the older term CLI because limb threat is a continuum, not just one pressure cutoff. original definition context.

Claudication is discomfort during activity that often eases with rest. Persistent symptoms at rest or a wound that fails to heal raise a different concern. Not every painful leg or ulcer is arterial; examination and blood-flow assessment establish what is contributing. different PAD symptoms.

A duration used in a clinical definition is not a reason to wait before seeking help. Describe a new wound or worsening pain when it occurs. CLTI and sudden acute limb ischemia can require different immediate decisions; the word “chronic” does not make a new change harmless.

Poor perfusion, nerve injury and infection can reinforce one another

Atherosclerotic plaque narrows or blocks arteries that carry oxygen-rich blood. PAD risk is associated with smoking, diabetes, kidney disease, high blood pressure and unhealthy cholesterol. These factors help explain risk without proving the cause of a particular wound. arterial-risk context.

Diabetes may also damage nerves, making an injury or ulcer less painful. Reduced arterial flow can impair healing at the same time. Therefore absence of pain is not a reliable assurance that a diabetic foot wound is safe. dated neuropathy and healing context.

Infection is a separate problem that can complicate tissue damage and threaten health beyond the limb. A dressing, an antibiotic and a circulation procedure address different parts of that problem. They should not be treated as interchangeable answers to every nonhealing wound. infection and blood-supply context.

Revascularisation and local wound care need coordinated planning

The 2024 guideline combines assessment for restoring perfusion with wound care, infection management and appropriate pressure offloading. Bypass, endovascular and combined procedures are chosen according to anatomy, available conduit, medical risk and personal goals. It supplies no single universal operation for CLTI. attributed planning framework.

Angioplasty opens an artery from within; bypass creates a route around a blockage. Medicines may address clotting, cholesterol and blood pressure. These are clinical roles, not a cleared independent ranking of drugs or devices. procedure and medicine context.

Before treatment, ask whether the main objective is pain relief, wound healing, preservation of a usable limb or several of these. Clarify what the team expects the procedure to change and which problems still need local care afterwards. A technically open artery and a healed, functional foot are different outcomes.

Wound-healing claims require human clinical evidence

The reviewed sources do not establish an independent supplement regimen that reverses CLTI or reliably prevents amputation. A nutrient deficiency or inadequate food intake may need clinical attention, but treating that separate problem does not demonstrate restoration of arterial supply.

Products promoted as angiogenesis boosters, circulation enhancers or antioxidants need evidence for human wound healing, function and safety. Laboratory activity alone cannot supply it. Report herbs and vitamins before a procedure because some can affect bleeding or anaesthesia. January 2019 safety context.

Protect the foot and make the care plan practical

Regular foot checks can reveal an injury that neuropathy conceals. Ask for help if you cannot see or reach the foot. Protect it from footwear pressure, barefoot injury and direct heat; do not use a hot-water bottle to treat a cold, insensate foot. dated foot-protection context.

Poor circulation needs professional assessment before compression bandages or stockings are applied. Venous-ulcer instructions cannot simply be copied for an ischemic wound. The NHS diagnostic page makes this safety distinction; its November 2022 review date is retained here. compression and arterial-pressure context.

Ask for specific guidance on mobility and pressure offloading rather than walking through a wound or severe rest pain. Smoking cessation, diabetes care and cardiovascular risk management remain part of PAD care, with activity adapted to the established limb problem. general long-term care context.

Know when the limb or an infection needs emergency care

A suddenly colder or paler foot, new loss of sensation or movement, or marked pain at rest needs emergency assessment for acute limb ischemia. An existing chronic wound does not rule out an added acute problem. acute warning signs.

Seek urgent care for new redness, swelling, pus, fever or chills associated with a foot wound. Deep infection may require hospital treatment, and poor blood supply can complicate healing. Follow an agreed urgent contact pathway rather than waiting for the next dressing appointment. wound-infection context.

Confusion, rapid or difficult breathing, marked deterioration or concerning blue-grey/pale/blotchy skin with illness may indicate sepsis. Get emergency help; not every sign has to appear. A person who feels seriously unwell should not wait to confirm whether the wound is the source. current sepsis safety guidance.

Clot-prevention and cholesterol medicines need separate safety review

Clopidogrel can interact with other clot-prevention medicines, NSAID painkillers, some antidepressants and certain heartburn medicines. Omeprazole and esomeprazole can affect its action. Do not add or remove a prescribed combination yourself; ask the pharmacist to check the full list. March 2025 interaction guidance.

If an anticoagulant is prescribed, bleeding, a significant injury or a head injury needs prompt advice. Medicine, herb, dental and surgical precautions depend on the actual drug. Warfarin food advice is not a rule for every anticoagulant. bleeding precautions; different interaction requirements.

Statins also need review when certain antibiotics, antifungals, other medicines or grapefruit are involved. Report possible adverse effects and check the exact product leaflet; the appropriate response differs between statins and combinations. May 2026 safety context.

Testing links the wound to objective arterial perfusion

Persistent rest pain, nonhealing wounds or tissue death merit prompt vascular assessment. Bring a timeline of symptoms, photographs if useful, prior vascular procedures and the medicine list. Explain how the problem affects sleep, walking, footwear and daily function.

Assessment includes examination, blood-flow testing and imaging when needed to plan care. Arm–ankle pressures, ultrasound and angiography answer different questions; the appearance of a wound alone does not map all diseased arteries. diagnostic-test purposes.

A falsely high ankle pressure from noncompressible arteries can require toe or other local perfusion tests. The 2024 guideline includes these additional measures in suspected CLTI. A reassuring-looking ankle number cannot always be interpreted in isolation. testing limitation.

WIfI grades wound extent, ischemia and foot infection together. It is a clinical staging framework, not a home calculator that guarantees a personal outcome. original staging context.

Amputation decisions, recovery and goals need explicit discussion

The 2024 guideline calls for experienced multidisciplinary review of options and personal goals before non-emergency major amputation. Life-threatening infection or a nonviable, nonfunctional limb may change the decision. Amputation is not automatically evidence that care has failed. attributed decision framework.

If the team describes “no-option” disease, ask what makes further restoration of arterial flow unsuitable and which pain, wound and function goals remain achievable. Request an explanation of expected treatment burden and the uncertainty of any proposed newer procedure. This guide gives no unverified salvage claim.

Agree who coordinates follow-up and how wound progress, perfusion, mobility and adverse effects will be assessed. PAD care also considers heart attack and stroke risk and quality of life. A successful local procedure does not end broader cardiovascular care. distinct care goals.

Cell, gene and vessel-growth findings are not routine treatment proof

A biological signal of new vessel growth does not establish durable human circulation, complete wound healing or safe long-term function. This article excludes animal and in-vitro outcomes from efficacy conclusions.

The dated global guideline treats regenerative approaches as research requiring rigorous clinical trials. We do not infer that a marketed stem-cell or gene procedure is independently proven from a laboratory mechanism. Current authorisation and trial evidence would require a separate product-specific assessment. bounded experimental-evidence context.

Funding and source roles

US and UK public education is separated from society-funded expert recommendations. The 2019 global project reports no direct industry support, while its author table contains company ties. Current foundation and registry partnerships are specific relationships, not proof those donors financed the old guideline. Complete WFVS finances and some page/reviewer chains remain unresolved.

Tier describes financial proximity; A–D describes credibility for the stated source role. Neither is a clinical certainty grade. Unknown finances remain unknown. Manufacturer- and sponsor-funded efficacy is excluded from the independent verdict; attributed clinical guidance is identified as guidance.

Frequently asked questions

Are CLTI and critical limb ischaemia the same term?
CLI is older terminology. CLTI emphasises the clinical spectrum of limb threat and objective arterial assessment.

Can an ulcer be serious if it does not hurt?
Yes. Diabetic nerve injury can reduce pain perception. Wound and circulation assessment still matter.

Does a high ankle pressure exclude arterial disease?
No. Noncompressible arteries can make the number misleading; clinicians may use additional tests.

Should I wear compression stockings for any leg wound?
No. The arterial supply and wound cause need assessment first.

Does a reopened artery guarantee healing?
No. Infection, tissue damage, pressure and wider health can still affect the outcome.

Is amputation always avoidable?
No. Some situations threaten life or leave nonviable tissue; clinical options and goals need an individual discussion.

Sources and funding notes

Original 2024 guideline clinical/method/disclosure text and the actual163-page 2019 JVS original PDF were opened. The 2019 paper is used for bounded definition/staging/experimental context, not a current device hierarchy or its old paclitaxel addendum. Current corporate-program originals were read with their entity and fiscal-period limits. NIDDK foot education is January 2017 and thanks external reviewer David Armstrong; his page-era financial chain is not cleared by a later unrelated author declaration. NIH budgets do not establish outside expert independence. No universal bypass-versus-endovascular verdict, numerical wound-healing guarantee or sponsor-funded efficacy is adopted.

• Original 2024 ACC/AHA multisociety lower-extremity PAD guideline — Clinical framework only; no independent device/drug ranking.
• 2024 PAD guideline: final Circulation original PDF — Original provenance and disclosure cross-check only.
• NHLBI: PAD overview (March 2022) — Arterial blood-flow and systemic atherosclerosis context; no old prevalence estimate adopted.
• NHLBI: PAD symptoms (March 2022) — Claudication, rest symptoms and wounds; symptoms do not establish the diagnosis.
• NHLBI: PAD causes (March 2022) — Plaque and risk-factor context; no genetic-test or stress-treatment efficacy claim.
• NHLBI: PAD diagnosis (March 2022) — History, pressure testing and imaging purposes; simplified ABI threshold not adopted.
• NHLBI: PAD treatment (March 2022) — Different treatment goals and procedure descriptions; exercise-first language not applied to threatened limbs.
• NHLBI: living with PAD (March 2022) — Emergency foot symptoms and foot care; coping is not claimed to extend life.
• NHS: PAD (April 2026) — Slow versus sudden symptoms and long-term cardiovascular context; blanket “not life-threatening” language not applied to limb emergencies.
• NHS: gangrene — Tissue death, urgent assessment and combined infection/blood-supply care; no oxygen-therapy efficacy conclusion.
• NHS: anticoagulant side effects (September 2024) — Bleeding and injury warning signs; no personal anticoagulant regimen.
• NHS: anticoagulant considerations (September 2024) — Medicine/herb interactions and planned procedures; no universal food restriction.
• NCCIH: supplement safety (January 2019) — Interaction and surgery disclosure only; no limb-salvage efficacy.
• AHA: original 2024–25 annual report — Institutional finance only.
• AHA: National Center contact — HQ trace only.
• ACC:2025 financial overview — Current financial-report status only.
• ACC: advertising opportunities — Advertising route, not evidence the guideline was bought.
• ACC: official contact — Headquarters only.
• NHLBI: budget and gift authority — Funding trace, not outcome evidence.
• NHS website: content and funding policy — Website funding and editorial safeguards only.
• Original 2019 Global Vascular Guidelines, JVS PDF — CLTI definition and WIfI context only; older device-safety addendum and treatment hierarchy not adopted.
• NIDDK: diabetes and feet (January 2017) — Neuropathy can hide injury; protection context only. Generic elevation/activity advice not applied to CLTI.
• NIDDK: own budget and legislative information — Own NIDDK finance; NHLBI allocations are not borrowed.
• SVS: corporate roundtable — Institutional industry route only.
• SVS Foundation: original FY 2025 report — Foundation relationship separately identified.
• SVS: headquarters contact — Headquarters only.
• ESVS: EVeR registry partnerships — Current institutional relationship context only.
• ESVS: administrative contact — Operational location only.
• NHS: clopidogrel interactions (March 2025) — Bleeding, stomach-medicine and supplement review; no fixed combination/dose.
• NHS: statins (May 2026) — Interaction and adverse-effect review only; no drug-efficacy hierarchy.
• NHS: ulcer diagnosis (November 2022) — Assess arterial flow before compression; passed 2025 review date retained.
• NHS: sepsis (May 2026) — Emergency systemic infection signs; not a self-diagnosis checklist.

Last reviewed: October 4, 2026. Educational information; no personal diagnosis, medication dose or supplement regimen is supplied. Local approval, product labels and clinical circumstances may differ.